ASP Isotopes Inc. — Q2 2023 Form 10-Q Summary
Business context and reporting period
ASP Isotopes Inc. is a pre-commercial advanced materials company developing its Aerodynamic Separation Process technology to enrich isotopes, initially C-14, Mo-100, Si-28 and potentially U-235. The company is completing and commissioning an isotope enrichment plant in South Africa and planning additional facilities. The unaudited report covers the three and six months ended June 30, 2023, with comparative periods ended June 30, 2022. Common stock trades on Nasdaq under ASPI; 37,385,684 shares were outstanding as of August 11, 2023.
Financial condition and key metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $252,880 | $460,214 |
| General and administrative expense | $4,094,664 | $7,612,154 |
| Total operating expenses | $4,347,544 | $8,072,368 |
| Operating loss | $(4,347,544) | $(8,072,368) |
| Net loss | $(4,286,346) | $(7,901,424) |
| Net loss per share, basic and diluted | $(0.14) | $(0.27) |
| Net cash used in operating activities | Not separately reported | $(2,701,890) |
Margins are not meaningful because the company had no revenue. Stock-based compensation was $2.375 million in the second quarter and $4.519 million for the six-month period, representing a significant portion of reported operating expenses.
- Cash was $3.626 million at June 30, 2023, compared with $2.389 million at December 31, 2022.
- Total assets were $12.751 million; property and equipment, primarily construction in progress, was $7.735 million.
- Total liabilities were $2.597 million, including $33,854 of notes payable, $694,750 of operating lease liabilities and $390,800 of share liabilities.
- The company reported no bank debt outstanding and no interest-rate exposure related to debt.
- Stockholders’ equity was $10.154 million, with an accumulated deficit of $15.454 million.
- Investing cash outflows were $508,607, primarily for construction in progress.
- Financing cash inflows were $4.494 million, consisting of net proceeds from the March 2023 private placement.
Material changes versus the prior comparable period
- Second-quarter net loss increased to $4.286 million from $827,170; six-month net loss increased to $7.901 million from $1.685 million.
- Second-quarter general and administrative expense increased to $4.095 million from $675,000; six-month expense increased to $7.612 million from $1.240 million. The increase was driven substantially by stock-based compensation, personnel costs and professional fees associated with operating as a public company.
- Second-quarter R&D expense increased to $253,000 from $153,000, while six-month R&D expense was broadly comparable with 2022 at $460,000 versus $446,000.
- Operating cash burn increased to $2.702 million for the first six months from $1.384 million in the prior-year period, despite substantial non-cash stock compensation.
- In March 2023, the company issued 3,164,557 common shares and warrants for gross proceeds of $5.0 million and received approximately $4.5 million net of offering costs.
- In April 2023, the company perfected its security interest in assets acquired from Klydon, including intellectual property. The transaction settled liabilities to Klydon totaling $626,223 through additional paid-in capital.
- Accumulated other comprehensive loss increased to $1.212 million, primarily due to foreign-currency translation losses.
Guidance, outlook, commentary, risks and unusual items
- Management expects substantial additional spending on development, construction, regulatory compliance and public-company infrastructure. The filing states that commercial revenues are not expected in substantial quantities until at least 2024, while U-235 commercialization, if permitted, would be several years away or may never occur.
- The initial Mo-100 plant phase has a stated contracted cost of $6.8 million and a planned capacity of at least five kilograms; a second phase would require an additional $6.0 million. Approximately $7.233 million had been paid under the Klydon turnkey contract and recorded in construction in progress, although Klydon failed to complete required services on schedule.
- The financial statements state that cash of $3.626 million is not expected to fund operating expenses and capital requirements for more than 12 months from issuance, raising substantial doubt about the company’s ability to continue as a going concern. Management expects to seek additional equity, debt or collaborative financing, but states that those plans were not yet probable.
- A separate risk-factor disclosure states that existing cash and recent financing were expected to fund operations for at least the next 12 months. This apparent inconsistency should be reconciled against the audited going-concern disclosure and current cash needs.
- The company has no approved products, no isotope sales and has not produced finished experimental isotope samples. Commercial success depends on demonstrating the technology, completing and commissioning facilities, obtaining required approvals and securing customers.
- The company received a letter from Norsk Medisinsk Syklotronsenter AS asserting that a former Klydon license may conflict with a pre-existing sublicense to Radfarma. Management believes the claims lack merit, but an adverse outcome could impair access to critical technology.
- Disclosure controls and procedures were ineffective as of June 30, 2023 because of a previously reported material weakness in internal control over financial reporting. Management plans to add accounting, finance and information-technology resources or consultants.
- Nasdaq notified the company in May 2023 that its bid price had fallen below $1.00; Nasdaq notified the company on August 11, 2023 that it had regained compliance.
- The company remains exposed to regulatory, nuclear non-proliferation, permitting, South African electricity and political risks, supplier concentration, foreign-exchange risk, intellectual-property disputes, dilution and the inability to obtain additional financing.
Important facts for investors to verify
- Reconcile the conflicting statements regarding whether available cash funds operations for at least 12 months and assess the probability and terms of required financing.
- Verify construction progress, remaining funding requirements, completion timing and performance obligations for the South African facility and the Klydon arrangements.
- Assess whether the ASP technology has been technically demonstrated at commercial scale and whether required permits and regulatory approvals remain valid and sufficient.
- Review the status and potential impact of the NMS/Radfarma intellectual-property dispute and the company’s ownership and enforceability of acquired technology.
- Quantify potential dilution from 3.386 million warrants, 2.851 million options, 6.868 million unvested restricted shares and future equity financings.
- Monitor remediation of the material weakness in internal controls and any subsequent changes in disclosure controls.
- Evaluate the sustainability of cash burn, the substantial non-cash stock compensation expense and the company’s ability to generate revenue or secure strategic funding.